. 코오롱제약

R&D

Research & Development

Kolon Pharmaceuticals is dedicated to innovating and creating value through relentless research and development.

Orthotopic Animal Model

Aids both independent & joint drug development via a global standard of orthotopic animal model services

Simulates the human body environment by injecting cancer cells into corresponding target organs in mice

Aims to create a model mirroring actual patient tumor tissues by interacting with the microscopic tumor environments.

  • Orthotopic Animal Model

    Comparison Items

    Orthotopic Animal Model

  • Subcutaneous Tissue

    Spread of generated area to other organs

    Same organ

  • Low

    Clinical replication success rate

    High

  • X

    Propagation to the identical organ

    O

  • X

    Interaction with adjacent tissues

    O

In vivo Anti-Cancer Effect

Unlike the ectopic animal model, cell inhibitory activity and apoptosis efficacy were confirmed in various solid cancer cell lines.
For the ectopic animal model, drug candidate B demonstrated the most significant decrease in tumor volume. However, in the orthotopic animal model, drug candidate A achieved the best results out of the three candidates. Pancreatic Cancer Orthotopic Model Test Results by PLATBIO

Ectopic Animal Model

Orthotopic Animal Model

  • Improved clinical trial success rate

  • Enhanced protocol completeness

  • Indication expansion

  • Fine-tuning of new drug candidates

  • License Out Deal

  • Reduction in Clinical Trial Costs

Expected Effects of Clinical Translation Research

Drastically enhance the efficiency and pace of new drug development.In the preclinical phase, diversify and validate drug applications and indications, enabling an effective clinical strategy formulation

01

Enhance the success potential of candidate substancesIf anticipated efficacy is not met during clinical stages, revert to the preclinical stage and pursue reverse translation research, including the development of alternate applications or further indication tests

02

Achieve Global-level License-Out (L/O) based on rigorous scientific verification, high-quality preclinical data, and a clinical strategy that increases the probability of success

03

PRIINT

A precise and swift tumor target discovery platform PRIINT has identified 50 new targets solely from pancreatic and ovarian cancer indications

Characteristics of PRIINT

01Creation of an orthotopic model tailored for specific tumors

02Discovery and validation of tumor targets

03Cross-validation of tumor targets using both tumor tissues and blood

Benefits of PRIINT

01Narrow the gap existing between preclinical and clinical stages

02Diminish both the costs and timeline associated with novel drug development

03Ensure cost-effective progression by leveraging existing clinical products

연구의뢰